| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Peter Jenne. Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease. Current opinion in neurology. vol 16 Suppl 1. 2004-07-20. PMID:15180131. |
dopamine agonists, receptor selectivity and dyskinesia induction in parkinson's disease. |
2004-07-20 |
2023-08-12 |
Not clear |
| Peter Jenne. Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease. Current opinion in neurology. vol 16 Suppl 1. 2004-07-20. PMID:15180131. |
long-acting dopamine agonists providing continuous, rather than pulsatile, dopaminergic stimulation appear able to avoid dyskinesia induction. |
2004-07-20 |
2023-08-12 |
Not clear |
| Olivier Bli. The pharmacokinetics of pergolide in Parkinson's disease. Current opinion in neurology. vol 16 Suppl 1. 2004-07-20. PMID:15180132. |
pergolide has a long half-life of about 21 h; this has interesting implications, as it should produce a more physiological or continuous stimulation of dopamine receptors, avoiding or delaying the induction of dyskinesia. |
2004-07-20 |
2023-08-12 |
Not clear |
| Johannes Schwar. Rationale for dopamine agonist use as monotherapy in Parkinson's disease. Current opinion in neurology. vol 16 Suppl 1. 2004-07-20. PMID:15180135. |
dopamine agonists are increasingly being used in the initial treatment of patients with de-novo parkinson's disease because they provide symptom relief and a low risk of the dyskinesia frequently associated with levodopa. |
2004-07-20 |
2023-08-12 |
Not clear |
| Ali H Rajput, Mark E Fenton, Thérèse Di Paolo, Harold Sitte, Christian Pifl, Oleh Hornykiewic. Human brain dopamine metabolism in levodopa-induced dyskinesia and wearing-off. Parkinsonism & related disorders. vol 10. issue 4. 2004-06-29. PMID:15120096. |
human brain dopamine metabolism in levodopa-induced dyskinesia and wearing-off. |
2004-06-29 |
2023-08-12 |
human |
| Ali H Rajput, Mark E Fenton, Thérèse Di Paolo, Harold Sitte, Christian Pifl, Oleh Hornykiewic. Human brain dopamine metabolism in levodopa-induced dyskinesia and wearing-off. Parkinsonism & related disorders. vol 10. issue 4. 2004-06-29. PMID:15120096. |
the objective of this study was to identify dopamine (da) metabolism pattern in lewy body parkinson's disease (pd) patients with dyskinesia (dysk) only, with wearing-off (wo) only, or no motor complications (nmc) induced by levodopa (ld). |
2004-06-29 |
2023-08-12 |
human |
| Vincent Paillé, Philippe Brachet, Philippe Damie. Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease. Neuroreport. vol 15. issue 3. 2004-05-20. PMID:15094523. |
to evaluate the relationship between the degree of dopamine neuron loss and the severity of dyskinesias in a rodent model of pd, sprague-dawley rats were lesioned unilaterally using different doses of 6-hydroxydopamine injected into the substantia nigra pars compacta (snc). |
2004-05-20 |
2023-08-12 |
human |
| Vincent Paillé, Philippe Brachet, Philippe Damie. Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease. Neuroreport. vol 15. issue 3. 2004-05-20. PMID:15094523. |
we found that a minimum dopamine cell loss of around 95% was required for the development of dyskinesias after one-month of levodopa treatment. |
2004-05-20 |
2023-08-12 |
human |
| Nancy Bélanger, Laurent Grégoire, Abdallah Hadj Tahar, Paul J Bédar. Chronic treatment with small doses of cabergoline prevents dopa-induced dyskinesias in parkinsonian monkeys. Movement disorders : official journal of the Movement Disorder Society. vol 18. issue 12. 2004-04-28. PMID:14673879. |
the pathophysiology of levodopa-induced dyskinesias (lid) is not completely understood, but it appears to result from deficient regulation by dopamine of corticostriatal glutamatergic inputs leading to a cascade of neurochemical changes in the striatum and the output pathways. |
2004-04-28 |
2023-08-12 |
monkey |
| Kathy Steece-Collier, Timothy J Collier, Paul D Danielson, Roger Kurlan, David M Yurek, John R Slade. Embryonic mesencephalic grafts increase levodopa-induced forelimb hyperkinesia in parkinsonian rats. Movement disorders : official journal of the Movement Disorder Society. vol 18. issue 12. 2004-04-28. PMID:14673880. |
recent observations from clinical trials of neural grafting for parkinson's disease (pd) have demonstrated that grafted dopamine neurons can worsen dyskinesias in some graft recipients. |
2004-04-28 |
2023-08-12 |
human |
| Andreas Kupsch, Thomas Trottenberg, Dirk Breme. Levodopa therapy with entacapone in daily clinical practice: results of a post-marketing surveillance study. Current medical research and opinion. vol 20. issue 1. 2004-04-21. PMID:14741081. |
the percentage of patients suffering from dyskinesia decreased from 46 to 34%, and of those patients still suffering from dyskinesia, the average daily duration of dyskinesia was reduced from 2.2 to 1.7 h. the use of adjunct dopamine agonists decreased from 67 to 59%. |
2004-04-21 |
2023-08-12 |
Not clear |
| Stephen C Fowler, Brenda Birkestrand, Rong Chen, Elena Vorontsova, Troy Zarcon. Behavioral sensitization to amphetamine in rats: changes in the rhythm of head movements during focused stereotypies. Psychopharmacology. vol 170. issue 2. 2004-04-12. PMID:12827349. |
the indirect-acting dopamine agonist amphetamine induces in rats, motor stereotypies that have served as the primary behavioral end points in studies related to schizophrenia, drug abuse, and l-dopa-induced dyskinesias. |
2004-04-12 |
2023-08-12 |
rat |
| Michael P Hill, Erwan Bezard, Steven G McGuire, Alan R Crossman, Jonathan M Brotchie, Ann Michel, Renee Grimée, Henrik Klitgaar. Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset. Movement disorders : official journal of the Movement Disorder Society. vol 18. issue 11. 2004-03-25. PMID:14639671. |
long-term dopamine replacement therapy of parkinson's disease leads to the occurrence of dyskinesias. |
2004-03-25 |
2023-08-12 |
marmoset |
| Michael P Hill, Erwan Bezard, Steven G McGuire, Alan R Crossman, Jonathan M Brotchie, Ann Michel, Renee Grimée, Henrik Klitgaar. Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset. Movement disorders : official journal of the Movement Disorder Society. vol 18. issue 11. 2004-03-25. PMID:14639671. |
thus, new nondopaminergic treatment strategies targeting normalization of abnormal firing patterns in basal ganglia structures may prove useful as an adjunct to reduce dyskinesia induced by dopamine replacement therapy without affecting its antiparkinsonian action. |
2004-03-25 |
2023-08-12 |
marmoset |
| Junchao Tong, Paul S Fitzmaurice, Lee Cyn Ang, Yoshiaki Furukawa, Mark Guttman, Stephen J Kis. Brain dopamine-stimulated adenylyl cyclase activity in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Annals of neurology. vol 55. issue 1. 2004-03-12. PMID:14705122. |
the dopamine d(1) receptor is considered to participate in levodopa's antiparkinsonian action and levodopa-induced dyskinesias. |
2004-03-12 |
2023-08-12 |
Not clear |
| Carlo Colosimo, Alessandra Crau. Noradrenergic drugs for levodopa-induced dyskinesia. Clinical neuropharmacology. vol 26. issue 6. 2004-02-06. PMID:14646609. |
the hypothesis is that because dopamine agonists are not metabolized to noradrenaline, alpha-2 adrenoreceptor antagonists do not reduce dyskinesia produced by such agents. |
2004-02-06 |
2023-08-12 |
Not clear |
| Peter Jenne. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurology. vol 62. issue 1 Suppl 1. 2004-02-04. PMID:14718680. |
current concepts suggest that avoidance of pulsatile stimulation of dopamine receptors in parkinson's disease (pd) can prevent the onset of dyskinesia. |
2004-02-04 |
2023-08-12 |
monkey |
| Peter Jenne. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurology. vol 62. issue 1 Suppl 1. 2004-02-04. PMID:14718680. |
in contrast, treatment with long-acting dopamine agonists leads to a much lower level of dyskinesia. |
2004-02-04 |
2023-08-12 |
monkey |
| Peter Jenne. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurology. vol 62. issue 1 Suppl 1. 2004-02-04. PMID:14718680. |
furthermore, the addition of multiple small doses of levodopa plus entacapone to dopamine agonist treatment also avoids dyskinesia induction in mptp-treated primates. |
2004-02-04 |
2023-08-12 |
monkey |
| Janet Romrell, Hubert H Fernandez, Michael S Oku. Rationale for current therapies in Parkinson's disease. Expert opinion on pharmacotherapy. vol 4. issue 10. 2003-12-18. PMID:14521485. |
trials with dopamine agonists have demonstrated a delay in the onset of dyskinesia with the use of this therapy. |
2003-12-18 |
2023-08-12 |
Not clear |